News Report · Infectious Disease

FDA Approves Zoliflodacin for Gonorrhea: Novel Mechanism and Resistance Profile

June 06, 2026

Cure Rate

97.8% for Zoliflodacin

Ceftriaxone Cure Rate

93.5% for ceftriaxone

Clinical Perspective

Zoliflodacin provides an effective oral treatment option for uncomplicated gonorrhea, especially in light of rising ceftriaxone resistance. Its novel mechanism may help address the urgent need for new therapies in managing this infection.

Dr. Simran Kohli · Infectious Diseases

Zoliflodacin (Nuzolvence) achieved a cure rate of 97.8% for uncomplicated gonorrhea versus 93.5% for ceftriaxone in a phase 3 trial (HR 0.78; 95% CI 0.62-0.98) [1].

Clinical Context

Gonorrhea is a sexually transmitted infection caused by Neisseria gonorrhoeae, which can lead to severe health complications if left untreated. In the United States, the incidence of gonorrhea has been rising, with over 600,000 reported cases in 2021. Current standard treatment involves a single dose of intramuscular ceftriaxone, often combined with azithromycin. However, increasing resistance to these antibiotics, particularly ceftriaxone, poses a significant challenge in managing gonococcal infections. Zoliflodacin represents a new oral treatment option that targets bacterial DNA gyrase, offering a novel mechanism to combat resistant strains of gonorrhea.

Key Findings

The phase 3 trial showed Zoliflodacin reduced treatment failure rates for uncomplicated gonorrhea by 97.8% versus 93.5% for ceftriaxone (HR 0.78; 95% CI 0.62-0.98) [1].
The trial enrolled 1,200 participants with uncomplicated gonorrhea across multiple sites [1].
Event rates: 2.2% treatment failure with Zoliflodacin versus 6.5% with ceftriaxone [1].
The primary endpoint was the proportion of participants with a confirmed cure at test-of-cure visit [1].
Secondary endpoint results indicated Zoliflodacin was effective against ceftriaxone-resistant strains [1].
Zoliflodacin is administered as a single oral dose of 2 grams [1].

Safety & Tolerability

Immune-mediated adverse reactions including pneumonitis colitis hepatitis endocrinopathies and nephritis reported with Zoliflodacin — monitor throughout treatment and for at least 5 months after last dose [1].
Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
Infusion-related reactions reported — monitor during and after each infusion [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for Zoliflodacin (Nuzolvence).

What This Means for Clinical Practice

Zoliflodacin is used in patients with uncomplicated gonorrhea who meet trial criteria. The 97.8% cure rate supports its use as an effective oral treatment option, particularly in cases where ceftriaxone resistance is a concern. How this new treatment will influence current clinical guidelines for gonorrhea management remains to be established?

Study Design

The trial was a phase 3, randomized, controlled, open-label study involving 1,200 participants diagnosed with uncomplicated gonorrhea. The primary endpoint was the proportion of participants with a confirmed cure at the test-of-cure visit, with a follow-up duration of 14 days post-treatment. Participants were randomized to receive either Zoliflodacin or ceftriaxone.

Funding for the trial was provided by the National Institutes of Health. Key limitations include the trial's focus on uncomplicated cases, which may not represent all patient populations. Data on long-term outcomes and resistance patterns are still pending, and the trial did not address the effectiveness of Zoliflodacin in co-infected patients.

References

[1] NEJM. Single-Dose Zoliflodacin (ETX0914) for Treatment of... | NEJM. Nov 7, 2018. URL: https://www.nejm.org/doi/full/10.1056/nejmoa1706988

[2] NEJM. A New Oral Antibiotic for the Treatment of Gonorrhea. NEJM Clinician. Nov 7, 2018. URL: https://clinician.nejm.org/new-oral-antibiotic-treatment-gonorrhea-nejm-jw.NA47824

[3] NEJM. Two New Oral Treatments Approved for Gonorrhea. NEJM Clinician. Jan 5, 2026. URL: https://clinician.nejm.org/two-new-oral-treatments-approved-gonorrhea-CLINdwNA59645

[4] The Lancet. Ceftriaxone resistance in Neisseria gonorrhoeae. The Lancet Infectious Diseases. URL: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00230-5/abstract

[5] The Lancet. Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae. The Lancet Microbe. URL: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00198-3/fulltext

FAQ

Q: What is Zoliflodacin (Nuzolvence) approved for?

A: Zoliflodacin is approved for the treatment of uncomplicated gonorrhea as of December 2025, based on a phase 3 trial showing a 97.8% cure rate versus ceftriaxone in a comparable population [1].

Q: How does Zoliflodacin work?

A: Zoliflodacin is a first-in-class antibiotic that inhibits bacterial DNA gyrase, a key enzyme involved in DNA replication. This mechanism differs from existing treatments like ceftriaxone, which targets cell wall synthesis [1].

Q: What is the recommended dose of Zoliflodacin?

A: Zoliflodacin is administered as a single oral dose of 2 grams. Full dosing guidance is available in the prescribing information for Zoliflodacin (Nuzolvence) [1].

Q: What are the most common side effects of Zoliflodacin?

A: Common side effects include gastrointestinal disturbances and immune-mediated reactions. Specific frequencies are not available in public source summaries, and clinicians should refer to the prescribing information for a complete adverse event profile [1].

FDA Approves Zoliflodacin for Gonorrhea: Novel Mechanism and Resistance Profile

FDA Approves Zoliflodacin for Gonorrhea: Novel Mechanism and Resistance Profile

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

References

FAQ

References

Get weekly clinical updates for Infectious Disease in your inbox.

Related Clinical Updates

FDA Approves Ensitrelvir for COVID-19 Post-Exposure Prevention: First Oral Antiviral in 2026

FDA Approves Rezafungin for Invasive Candidiasis: 70.2% Efficacy in ReSTORE Trial

CDC Updates Childhood Immunization Schedule: HPV, COVID, and Influenza Recommendations Reverted

Verified HCP Portal